Balassa Katalin, Danby Robert, Rocha Vanderson
Clinical Research Fellow in Bone Marrow Transplantation, Oxford University Hospitals NHS Foundation Trust, Department of Clinical Haematology, Cancer and Haematology Centre, Churchill Hospital, Headington, Oxford OX3 7LE and NHS Blood and Transplant, Oxford.
Consultant Haematologist, Oxford University Hospitals NHS Foundation Trust, Department of Clinical Haematology, Cancer and Haematology Centre, Churchill Hospital, Headington, Oxford and Anthony Nolan Research Institute, London.
Br J Hosp Med (Lond). 2019 Jan 2;80(1):33-39. doi: 10.12968/hmed.2019.80.1.33.
Haematopoietic stem cell transplantation was proposed as a treatment strategy just over 60 years ago. Owing to great advances in the field, haematopoietic stem cell transplantation has become an established method for the treatment of many haemato-oncological, immunological and hereditary conditions with the potential of cure. The number of haematopoietic stem cell transplants performed worldwide reached one million by 2012. This review provides an overview of autologous and allogeneic haematopoietic stem cell transplantation including disease indications, the individual steps of the procedure and outcome, and highlights achievements in the treatment of autoimmune diseases. Although autoimmune conditions account for only 1% of indications for autologous haematopoietic stem cell transplant, this is increasingly used to treat high-risk autoimmune diseases. Haematopoietic stem cell transplantation can induce long-term remission by resetting the immune system via eradication of autoreactive immune cells and the generation of a de novo self-tolerant immune system. Data seem most encouraging in multiple sclerosis and systemic sclerosis and it is likely that the number of procedures performed to treat these conditions will rise in the future.
造血干细胞移植在60多年前就被提出作为一种治疗策略。由于该领域的巨大进展,造血干细胞移植已成为治疗许多血液肿瘤、免疫和遗传疾病的既定方法,具有治愈的潜力。到2012年,全球进行的造血干细胞移植数量达到了100万例。本综述概述了自体和异体造血干细胞移植,包括疾病适应症、手术的各个步骤和结果,并重点介绍了自身免疫性疾病治疗方面的成就。尽管自身免疫性疾病仅占自体造血干细胞移植适应症的1%,但它越来越多地用于治疗高危自身免疫性疾病。造血干细胞移植可以通过根除自身反应性免疫细胞和产生全新的自我耐受免疫系统来重置免疫系统,从而诱导长期缓解。在多发性硬化症和系统性硬化症方面,数据似乎最令人鼓舞,未来用于治疗这些疾病的手术数量可能会增加。